You are here
Positive Early Data Announced for Three Investigational Triple Combination CF Medicines
Positive Initial Phase 1 & Phase 2 Data Announced from Three Investigational Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)
July 18, 2017
Vertex announced initial positive data from Phase 1 and Phase 2 studies of three investigational triple combination regimens in people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min). These early data suggest that these investigational combinations may have a role in treating the underlying cause of CF in people who have a severe and difficult-to-treat type of the disease. Vertex also released early Phase 2 study data for two of the triple combination regimens in people with CF who have two copies of the F508del mutation.